Overview
Phesi provides AI-driven patient-centric data analytics through its Trial Accelerator platform, simulating clinical trials with data from over 132 million patients across 4,000 diseases and 485,000 trials. The platform supports protocol design, site selection, patient enrollment forecasting, and digital twins for external control arms to optimize trial efficiency and diversity. Trusted by leading pharmaceutical companies, it accelerates development for rare and common indications in nearly 200 countries.
Frequently asked questions
- What is Phesi's Trial Accelerator platform?
- Trial Accelerator is an AI-powered platform with data from 132 million patients, enabling simulation of trial design, protocol optimization, enrollment forecasting, and patient diversity analysis across 4,000 diseases and 485,000 trials.
- What clinical development services does Phesi offer?
- Services include protocol design, site selection, patient enrollment modeling, digital patient profiles, digital twins, and external control arms, covering the full clinical development workflow from planning to execution.
- What geographic coverage and data scale does Phesi provide?
- Phesi covers nearly 200 countries with trial and site data from 600,000 principal investigators, drawing from over 70,000 real-time sources including clinical trials and real-world patient records.